VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia

被引：10

作者：

Ataergin, Selmin ^{[1
]}

Arpaci, Fikret ^{[1
]}

Kaya, Ayper ^{[1
]}

Kaya, Turker ^{[1
]}

Gunhan, Omer ^{[1
]}

机构：

[1] GATA Gulhane Fac Med, Med Oncol & Bone Marrow Transplantat Unit, Ankara, Turkey

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2006年 / 81卷 / 12期

关键词：

D O I：

10.1002/ajh.20672

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：987 / 988

页数：2

共 5 条

[1] Long-term disease-free survival in a primary plasma cell leukemia treated by VAD, autologous PBSC transplantation, and IFN-α [J].

Buchler, T ;

Ferra, C ;

Domingo, A ;

Gallardo, D ;

Sarra, J ;

Granena, A .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (01) :62-62

[2] Bortezomib is an efficient agent in plasma cell leukemias [J].

Esparís-Ogando, A ;

Alegre, A ;

Aguado, B ;

Mateo, G ;

Gutiérrez, N ;

Bladé, J ;

Schenkein, D ;

Pandiella, A ;

San Miguel, JF .

INTERNATIONAL JOURNAL OF CANCER, 2005, 114 (04) :665-667

[3]

Gotoh H, 1991, Rinsho Ketsueki, V32, P822

[4] Plasma cell leukemia [J].

Hayman S.R. ;

Fonseca R. .

Current Treatment Options in Oncology, 2001, 2 (3) :205-216

[5] A phase 2 study of bortezomib in relapsed, refractory myeloma [J].

Richardson, PG ;

Barlogie, B ;

Berenson, J ;

Singhal, S ;

Jagannath, S ;

Irwin, D ;

Rajkumar, SV ;

Srkalovic, G ;

Alsina, M ;

Alexanian, R ;

Siegel, D ;

Orlowski, RZ ;

Kuter, D ;

Limentani, SA ;

Lee, S ;

Hideshima, T ;

Esseltine, DL ;

Kauffman, M ;

Adams, J ;

Schenkein, DP ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) :2609-2617

← 1 →